Breaking News Instant updates and real-time market news.

CNST

Constellation Pharmaceuticals

$33.62 /

-0.02 (-0.06%)

09:08
06/11/21
06/11
09:08
06/11/21
09:08

Constellation Pharmaceuticals announces posters on ongoing MANIFEST study

Constellation Pharmaceuticals announced that three posters relating to the MANIFEST clinical trial of pelabresib in myelofibrosis were published online in association with the European Hematology Association annual meeting. The data in these posters are based on a data cutoff of September 29, 2020 from the MANIFEST Phase 2 clinical trial and reflect an analysis of pelabresib clinical and translational activity. Translational data, across all three arms of the Phase 2 MANIFEST study, support the disease-modifying potential of pelabresib: Centrally reviewed bone marrow fibrosis pathology conducted in 63 patients showed similar improvements as reported previously for local review of BMF grade. 23 out of 63 patients achieved at least a 1 grade improvement in BMF. Of these patients, 83% achieved improvements in BMF by 24 weeks. 17% of the patients with BMF improvement, improved by at least 2 grades. 31 out of 63 patients were stabilized or had no change, and only 4 out of 63 patients worsened. An increase in BM erythroid progenitor cells and reduction of the number and cluster formation of megakaryocytes in the BM was observed in 59% and 65%, respectively, of 37 samples from patients treated with pelabresib either as a monotherapy or in combination with ruxolitinib. Pelabresib durably reduced inflammatory cytokines such as tumor necrosis factor alpha and interleukin 18 as early as 2 weeks and maintained through 24 weeks of treatment, based on an analysis of patient samples. Arm 3 - CPI-0610 + ruxolitinib interim efficacy subgroup analysis in JAK-inhibitor-naive patients. As previously reported at ASH 2020, 42 of 63 evaluable patients achieved a greater than or equal to35% reduction in spleen volume at 24 weeks. 34 of 60 evaluable patients achieved a greater than or equal to50% reduction in Total Symptom Scores at 24 weeks. Strong response was observed with pelabresib, irrespective of baseline risk status or demographic and disease characteristics. Central pathology review of 27 1L patient bone marrow samples showed at least a one-grade improvement in bone marrow fibrosis in 9 out of 27 patients; in all of these patients, improvement was observed within 6 months of starting treatment. 16 out of 27 patients showed stabilization of bone marrow fibrosis, while only 1 out of 27 patients showed worsening. Arm 1 and 2 - Interim analysis demonstrating that pelabresib monotherapy in JAK-inhibitor-experienced or -ineligible patients, and with pelabresib + ruxolitinib in ruxolitinib-experienced patients, resulted in improvements in anemia: As previously reported at ASH 2020, 3 of 14 evaluable Transfusion Dependent patients in Arm 1A achieved transfusion independence and 13 of 36 evaluable TD patients in Arm 2A achieved transfusion independence. 9 out of 15 evaluable TD patients in Arm 1A, and 25 out of 47 of evaluable TD patients in Arm 2A achieved a greater than or equal to50% reduction in red blood cell transfusions. As of the September 29, 2020 data cutoff, pelabresib was generally well tolerated in MANIFEST, both as monotherapy and in combination with ruxolitinib, and in both JAK-inhibitor-naive and -ineligible as well as JAK-inhibitor-experienced patients. Among the most common treatment-emergent adverse events for CPI-0610 monotherapy in 46 safety-evaluable patients in Arm 1, those that were Grade 3 were thrombocytopenia, anemia, diarrhea, constipation, respiratory tract infection, and weight decrease. Amongst the most common TEAEs, there were no Grade 4. Other Grade 3/4 TEAEs include hyperuricemia, hyperkalemia and dyspnea. Nine patients discontinued treatment because of TEAEs. No Grade 5 events were observed. Among the most common TEAEs in 78 safety-evaluable patients in Arm 2, those that were Grade 3 were thrombocytopenia, anemia, respiratory tract infections, diarrhea, asthenic conditions, and nausea. Amongst the most common TEAEs, Grade 4 events included thrombocytopenia and anemia. Nine patients discontinued treatment due to TEAEs, including six Grade 5 TEAEs, which were acute kidney injury, traumatic subdural hematoma, brain stem hemorrhage, disease progression, congestive heart failure, and transformation to AML. Among the most common TEAEs in 78 safety-evaluable patients in Arm 3, those that were Grade 3 were anemia and thrombocytopenia. Amongst the most common TEAEs, Grade 4 events included thrombocytopenia, anemia, and respiratory tract infection. Two patients discontinued treatment due to TEAEs. In addition, there were two Grade 5 TEAEs, each resulting from multi-organ failure due to sepsis.

  • 17

    Jun

CNST Constellation Pharmaceuticals
$33.62 /

-0.02 (-0.06%)

06/03/21 Jefferies
Constellation Pharmaceuticals downgraded to Hold from Buy at Jefferies
06/03/21 Truist
Constellation Pharmaceuticals downgraded to Hold from Buy at Truist
06/03/21 SVB Leerink
MorphoSys upgraded to Outperform at SVB Leerink
06/03/21 Cowen
Constellation Pharmaceuticals downgraded to Market Perform from Outperform at Cowen

TODAY'S FREE FLY STORIES

Periodicals
Missouri Cobalt working with Goldman to explore possible SPAC deal, Reuters says » 14:33
06/18/21
06/18
14:33
06/18/21
14:33
MP

MP Materials

$31.32 /

-1.08 (-3.33%)

, GS

Goldman Sachs

$350.61 /

-10.99 (-3.04%)

Missouri Cobalt has hired…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MP MP Materials
$31.32 /

-1.08 (-3.33%)

GS Goldman Sachs
$350.61 /

-10.99 (-3.04%)

MP MP Materials
$31.32 /

-1.08 (-3.33%)

06/16/21 JPMorgan
MP Materials initiated with an Overweight at JPMorgan
04/01/21 BofA
MP Materials initiated with a Neutral at BofA
03/10/21 Cowen
MP Materials initiated with an Outperform at Cowen
03/09/21 Deutsche Bank
MP Materials downgraded to Hold on valuation at Deutsche Bank
GS Goldman Sachs
$350.61 /

-10.99 (-3.04%)

06/17/21 JMP Securities
Goldman Sachs price target raised to $425 from $400 at JMP Securities
06/16/21 JPMorgan
Goldman Sachs price target raised to $452 from $351 at JPMorgan
06/09/21 Jefferies
Jefferies starts 'too cheap' Goldman Sachs at Buy
06/09/21 Jefferies
Goldman Sachs initiated with a Buy at Jefferies
MP MP Materials
$31.32 /

-1.08 (-3.33%)

GS Goldman Sachs
$350.61 /

-10.99 (-3.04%)

  • 24
    Mar
GS Goldman Sachs
$350.61 /

-10.99 (-3.04%)

MP MP Materials
$31.32 /

-1.08 (-3.33%)

GS Goldman Sachs
$350.61 /

-10.99 (-3.04%)

MP MP Materials
$31.32 /

-1.08 (-3.33%)

GS Goldman Sachs
$350.61 /

-10.99 (-3.04%)

Options
Arcimoto call volume above normal and directionally bullish » 14:25
06/18/21
06/18
14:25
06/18/21
14:25
FUV

Arcimoto

$14.42 /

+0.02 (+0.14%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FUV Arcimoto
$14.42 /

+0.02 (+0.14%)

FUV Arcimoto
$14.42 /

+0.02 (+0.14%)

04/01/21
Fly Intel: Top five analyst downgrades
04/01/21 H.C. Wainwright
Arcimoto downgraded to Neutral from Buy at H.C. Wainwright
01/25/21 Roth Capital
Roth not expecting major reaction in stock following Arcimoto Q4 deliveries miss
08/20/20 Roth Capital
Arcimoto downgraded to Neutral from Buy at Roth Capital
FUV Arcimoto
$14.42 /

+0.02 (+0.14%)

FUV Arcimoto
$14.42 /

+0.02 (+0.14%)

FUV Arcimoto
$14.42 /

+0.02 (+0.14%)

FUV Arcimoto
$14.42 /

+0.02 (+0.14%)

General news
Wall Street remained lower into the close » 14:20
06/18/21
06/18
14:20
06/18/21
14:20
$ECON

Economic Data

/

+

Wall Street remained…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

Technical Analysis
On The Fly: ETF fund flow highlights » 14:19
06/18/21
06/18
14:19
06/18/21
14:19
XBI

SPDR S&P BIOTECH

$132.86 /

-1.41 (-1.05%)

, IBB

iShares Nasdaq Biotechnology Index

$157.39 /

-1.88 (-1.18%)

, JNK

SPDR Barclays High Yield Bond

$109.30 /

-0.09 (-0.08%)

, SHY

iShares 1-3 Year Treasury Bond

$86.10 /

-0.075 (-0.09%)

, HYG

iShares iBoxx $ High Yield Corporate Bond

$87.42 /

-0.075 (-0.09%)

, SPY

SPDR S&P 500 ETF Trust

$416.85 /

-3.754125 (-0.89%)

, TLT

iShares 20+ Year Treasury Bond Fund

$145.70 /

+2.65 (+1.85%)

, LQD

iShares iBoxx $ Investment Grade Corporate Bond

$134.35 /

+0.71 (+0.53%)

, QQQ

Invesco QQQ Trust

$343.75 /

-1.59 (-0.46%)

, IVV

iShares Core S&P 500

$418.65 /

-3.8 (-0.90%)

For the week there was a…

For the week there was a very heavy skew to creations versus redemptions in the top twenty dollar volume flows, but much of that skew is likely related to Russell Reconstitution. Excluding that activity, the two standouts among inflows were the iShares Core S&P 500 ETF (IVV), Invesco QQQ Trust (QQQ), iShares iBoxx USD Investment Grade Corporate Bond ETF (LQD), and iShares 20+ Year Treasury Bond ETF (TLT). In sum those ETFs comprised over 37% of creations. On the redemptions side the single largest outflow was from the SPDR S&P 500 ETF Trust (SPY) at over 30% of outflows. Bonds saw significant redemptions in the form of the iShares iBoxx USD High Yield Corporate Bond ETF (HYG), iShares 1-3 Year Treasury Bond ETF (SHY), and SPDR Bloomberg Barclays High Yield Bond ETF (JNK). Those ETFs made up over 20% of volume. Biotech saw notable outflows as well from the iShares Biotechnology ETF (IBB) and SPDR S&P Biotech ETF (XBI) at over 13% of volume.

ShowHide Related Items >><<
SPY SPDR S&P 500 ETF Trust
$416.85 /

-3.754125 (-0.89%)

LQD iShares iBoxx $ Investment Grade Corporate Bond
$134.35 /

+0.71 (+0.53%)

QQQ Invesco QQQ Trust
$343.75 /

-1.59 (-0.46%)

XBI SPDR S&P BIOTECH
$132.86 /

-1.41 (-1.05%)

IBB iShares Nasdaq Biotechnology Index
$157.39 /

-1.88 (-1.18%)

JNK SPDR Barclays High Yield Bond
$109.30 /

-0.09 (-0.08%)

SHY iShares 1-3 Year Treasury Bond
$86.10 /

-0.075 (-0.09%)

HYG iShares iBoxx $ High Yield Corporate Bond
$87.42 /

-0.075 (-0.09%)

SPY SPDR S&P 500 ETF Trust
$416.85 /

-3.754125 (-0.89%)

03/15/21 Morgan Stanley
Morgan Stanley equity strategist downgrades small cap stocks
03/12/21
On The Fly: Weekly technical notes for S&P 500
01/07/21 Credit Suisse
Credit Suisse raises 2021 S&P 500 target to 4,200, sees 12% upside
11/09/20 JPMorgan
JPMorgan sees S&P 500 hitting 4,000 by early next year
TLT iShares 20+ Year Treasury Bond Fund
$145.70 /

+2.65 (+1.85%)

LQD iShares iBoxx $ Investment Grade Corporate Bond
$134.35 /

+0.71 (+0.53%)

QQQ Invesco QQQ Trust
$343.75 /

-1.59 (-0.46%)

IVV iShares Core S&P 500
$418.65 /

-3.8 (-0.90%)

IBB iShares Nasdaq Biotechnology Index
$157.39 /

-1.88 (-1.18%)

SPY SPDR S&P 500 ETF Trust
$416.85 /

-3.754125 (-0.89%)

XBI SPDR S&P BIOTECH
$132.86 /

-1.41 (-1.05%)

HYG iShares iBoxx $ High Yield Corporate Bond
$87.42 /

-0.075 (-0.09%)

TLT iShares 20+ Year Treasury Bond Fund
$145.70 /

+2.65 (+1.85%)

LQD iShares iBoxx $ Investment Grade Corporate Bond
$134.35 /

+0.71 (+0.53%)

QQQ Invesco QQQ Trust
$343.75 /

-1.59 (-0.46%)

JNK SPDR Barclays High Yield Bond
$109.30 /

-0.09 (-0.08%)

HYG iShares iBoxx $ High Yield Corporate Bond
$87.42 /

-0.075 (-0.09%)

SPY SPDR S&P 500 ETF Trust
$416.85 /

-3.754125 (-0.89%)

TLT iShares 20+ Year Treasury Bond Fund
$145.70 /

+2.65 (+1.85%)

LQD iShares iBoxx $ Investment Grade Corporate Bond
$134.35 /

+0.71 (+0.53%)

QQQ Invesco QQQ Trust
$343.75 /

-1.59 (-0.46%)

IVV iShares Core S&P 500
$418.65 /

-3.8 (-0.90%)

Technical Analysis
NASDAQ market internals summary » 14:17
06/18/21
06/18
14:17
06/18/21
14:17
$NSD

NASDAQ Market Internals

/

+

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
/

+

Technical Analysis
NYSE market internals summary » 14:16
06/18/21
06/18
14:16
06/18/21
14:16
$NYE

NYSE Market Internals

/

+

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$NYE NYSE Market Internals
/

+

Conference/Events
TowneBank participates in a conference call with Stephens » 14:10
06/18/21
06/18
14:10
06/18/21
14:10
TOWN

TowneBank

$29.74 /

-1.1 (-3.57%)

Banks-East…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TOWN TowneBank
$29.74 /

-1.1 (-3.57%)

02/03/21 Piper Sandler
TowneBank upgraded to Overweight from Neutral at Piper Sandler
08/03/20 Piper Sandler
TowneBank resumed with a Neutral at Piper Sandler
TOWN TowneBank
$29.74 /

-1.1 (-3.57%)

Conference/Events
Howard Bancorp participates in a conference call with Stephens » 14:07
06/18/21
06/18
14:07
06/18/21
14:07
HBMD

Howard Bancorp

$16.14 /

-0.36 (-2.18%)

Banks-East…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HBMD Howard Bancorp
$16.14 /

-0.36 (-2.18%)

04/27/21 Stephens
Howard Bancorp upgraded to Overweight following Q1 report at Stephens
04/27/21 Stephens
Howard Bancorp upgraded to Overweight from Equal Weight at Stephens
03/11/21 Piper Sandler
Howard Bancorp initiated with an Overweight at Piper Sandler
HBMD Howard Bancorp
$16.14 /

-0.36 (-2.18%)

Options
Lemonade call volume above normal and directionally bullish » 14:05
06/18/21
06/18
14:05
06/18/21
14:05
LMND

Lemonade

$103.02 /

+3.78 (+3.81%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LMND Lemonade
$103.02 /

+3.78 (+3.81%)

LMND Lemonade
$103.02 /

+3.78 (+3.81%)

05/13/21 Barclays
Lemonade price target lowered to $71 from $101 at Barclays
04/28/21
Fly Intel: Top five analyst initiations
04/27/21 Credit Suisse
Lemonade assumed with an Underperform at Credit Suisse
04/20/21 JMP Securities
JMP Securities reiterates Outperform on Lemonade amid auto insurance entrance
LMND Lemonade
$103.02 /

+3.78 (+3.81%)

  • 14
    Jan
  • 02
    Jul
LMND Lemonade
$103.02 /

+3.78 (+3.81%)

LMND Lemonade
$103.02 /

+3.78 (+3.81%)

LMND Lemonade
$103.02 /

+3.78 (+3.81%)

Conference/Events
OceanFirst Financial participates in a conference call with Stephens » 14:00
06/18/21
06/18
14:00
06/18/21
14:00
OCFC

OceanFirst Financial

$20.67 /

-0.79 (-3.68%)

Conference call with CEO…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
OCFC OceanFirst Financial
$20.67 /

-0.79 (-3.68%)

05/06/21
Fly Intel: Top five analyst downgrades
05/06/21 Stephens
OceanFirst downgraded to Equal Weight at Stephens after NIM disappoints
05/06/21 Stephens
OceanFirst Financial downgraded to Equal Weight from Overweight at Stephens
03/24/21 Seaport Global
OceanFirst Financial initiated with a Buy at Seaport Global
OCFC OceanFirst Financial
$20.67 /

-0.79 (-3.68%)

Recommendations
McPhy Energy price target lowered to EUR 41 from EUR 49 at Barclays » 14:00
06/18/21
06/18
14:00
06/18/21
14:00
MPHYF

McPhy Energy

$34.25 /

+ (+0.00%)

Barclays analyst James…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MPHYF McPhy Energy
$34.25 /

+ (+0.00%)

05:45 Today Berenberg
McPhy Energy downgraded to Hold from Buy at Berenberg
Recommendations
Henkel price target raised to EUR 102 from EUR 101 at Barclays » 13:59
06/18/21
06/18
13:59
06/18/21
13:59
HENKY

Henkel

$24.55 /

-0.17 (-0.69%)

Barclays analyst Iain…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HENKY Henkel
$24.55 /

-0.17 (-0.69%)

05/10/21 Barclays
Henkel price target lowered to EUR 101 from EUR 106 at Barclays
05/10/21 Berenberg
Henkel price target raised to EUR 100 from EUR 96 at Berenberg
05/07/21 RBC Capital
Henkel price target raised to EUR 114 from EUR 110 at RBC Capital
05/05/21 Deutsche Bank
Henkel price target raised to EUR 95 from EUR 90 at Deutsche Bank
General news
Action Economics Survey results » 13:55
06/18/21
06/18
13:55
06/18/21
13:55
$ECON

Economic Data

/

+

Action Economics Survey…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

Conference/Events
Wedbush banking/homebuilders analysts hold an analyst/industry conference call » 13:52
06/18/21
06/18
13:52
06/18/21
13:52

Regional Banks Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Options
PepsiCo call volume above normal and directionally bullish » 13:45
06/18/21
06/18
13:45
06/18/21
13:45
PEP

PepsiCo

$146.45 /

-2.06 (-1.39%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PEP PepsiCo
$146.45 /

-2.06 (-1.39%)

PEP PepsiCo
$146.45 /

-2.06 (-1.39%)

05/04/21 Piper Sandler
Teladoc closed down 5% on three year old 'news,' says Piper Sandler
05/03/21 Cantor Fitzgerald
Teladoc competitive loss a gain for Amwell, says Cantor Fitzgerald
04/21/21
Fly Intel: Top five analyst upgrades
04/21/21 UBS
PepsiCo upgraded to Buy from Neutral at UBS
PEP PepsiCo
$146.45 /

-2.06 (-1.39%)

PEP PepsiCo
$146.45 /

-2.06 (-1.39%)

PEP PepsiCo
$146.45 /

-2.06 (-1.39%)

PEP PepsiCo
$146.45 /

-2.06 (-1.39%)

Upgrade
Stifel upgrades Dynagas LNG to Buy as leverage comes down » 13:30
06/18/21
06/18
13:30
06/18/21
13:30
DLNG

Dynagas LNG

$2.97 /

-0.16 (-5.11%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DLNG Dynagas LNG
$2.97 /

-0.16 (-5.11%)

DLNG Dynagas LNG
$2.97 /

-0.16 (-5.11%)

13:26 Today Stifel
Dynagas LNG upgraded to Buy from Hold at Stifel
01/29/21 Jefferies
Dynagas LNG price target raised to $3 from $2.50 at Jefferies
DLNG Dynagas LNG
$2.97 /

-0.16 (-5.11%)

DLNG Dynagas LNG
$2.97 /

-0.16 (-5.11%)

General news
Oil Action: The weekly Baker Hughes oil rig coun » 13:30
06/18/21
06/18
13:30
06/18/21
13:30
$ECON

Economic Data

/

+

Oil Action: The weekly…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

Upgrade
Dynagas LNG upgraded to Buy from Hold at Stifel » 13:26
06/18/21
06/18
13:26
06/18/21
13:26
DLNG

Dynagas LNG

$2.97 /

-0.16 (-5.11%)

Stifel analyst Benjamin…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DLNG Dynagas LNG
$2.97 /

-0.16 (-5.11%)

DLNG Dynagas LNG
$2.97 /

-0.16 (-5.11%)

01/29/21 Jefferies
Dynagas LNG price target raised to $3 from $2.50 at Jefferies
DLNG Dynagas LNG
$2.97 /

-0.16 (-5.11%)

DLNG Dynagas LNG
$2.97 /

-0.16 (-5.11%)

Options
Bilibili call volume above normal and directionally bullish » 13:25
06/18/21
06/18
13:25
06/18/21
13:25
BILI

Bilibili

$118.20 /

+3.89 (+3.40%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BILI Bilibili
$118.20 /

+3.89 (+3.40%)

BILI Bilibili
$118.20 /

+3.89 (+3.40%)

05/14/21 86 Research
Bilibili upgraded to Buy from Hold at 86 Research
04/19/21 CLSA
Bilibili initiated with a Buy, $128 target at CLSA
04/08/21
Fly Intel: Top five analyst upgrades
04/08/21 Credit Suisse
Bilibili upgraded to Outperform at Credit Suisse after recent pullback
BILI Bilibili
$118.20 /

+3.89 (+3.40%)

BILI Bilibili
$118.20 /

+3.89 (+3.40%)

BILI Bilibili
$118.20 /

+3.89 (+3.40%)

BILI Bilibili
$118.20 /

+3.89 (+3.40%)

Hot Stocks
Washington State University to review claims about Athira Pharma CEO » 13:17
06/18/21
06/18
13:17
06/18/21
13:17
ATHA

Athira Pharma

$11.40 /

-6.83 (-37.47%)

Washington State…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ATHA Athira Pharma
$11.40 /

-6.83 (-37.47%)

ATHA Athira Pharma
$11.40 /

-6.83 (-37.47%)

09:25 Today Jefferies
Athira Pharma's 'unusual situation' to cause some volatility, says Jefferies
07:25 Today Stifel
Athira Pharma CEO leave situation 'impossible to really vet,' says Stifel
06/07/21 JMP Securities
Aducanumab accelerated approval positive for Athira, others, says JMP Securities
06/07/21 Goldman Sachs
Goldman says Biogen approval has positive read to Alector, Athira
ATHA Athira Pharma
$11.40 /

-6.83 (-37.47%)

  • 21
    Jan
  • 18
    Sep
ATHA Athira Pharma
$11.40 /

-6.83 (-37.47%)

ATHA Athira Pharma
$11.40 /

-6.83 (-37.47%)

Technical Analysis
NASDAQ market internals summary » 13:17
06/18/21
06/18
13:17
06/18/21
13:17
$NSD

NASDAQ Market Internals

/

+

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
/

+

Technical Analysis
NYSE market internals summary » 13:16
06/18/21
06/18
13:16
06/18/21
13:16
$NYE

NYSE Market Internals

/

+

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$NYE NYSE Market Internals
/

+

Conference/Events
Universal Display participates in a conference call with Needham » 13:11
06/18/21
06/18
13:11
06/18/21
13:11
OLED

Universal Display

$210.53 /

-5.13 (-2.38%)

Conference call with…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OLED Universal Display
$210.53 /

-5.13 (-2.38%)

OLED Universal Display
$210.53 /

-5.13 (-2.38%)

05/19/21 Citi
Universal Display upgraded to Buy from Neutral at Citi
05/19/21 Citi
Universal Display upgraded to Buy from Neutral at Citi
03/08/21 Evercore ISI
Evercore ISI 'emphatically' reiterates Outperform rating on Universal Display
03/08/21 Roth Capital
Universal Display upgraded to Buy at Roth Capital
OLED Universal Display
$210.53 /

-5.13 (-2.38%)

OLED Universal Display
$210.53 /

-5.13 (-2.38%)

Conference/Events
Domo participates in a conference call with Needham » 13:10
06/18/21
06/18
13:10
06/18/21
13:10
DOMO

Domo

$78.15 /

+1.26 (+1.64%)

Conference call with…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DOMO Domo
$78.15 /

+1.26 (+1.64%)

DOMO Domo
$78.15 /

+1.26 (+1.64%)

05/28/21 Needham
Domo price target raised to $93 from $91 at Needham
03/15/21 Credit Suisse
Domo assumed with a Neutral at Credit Suisse
03/15/21
Fly Intel: Top five analyst upgrades
03/15/21 UBS
Domo upgraded to Buy from Neutral at UBS
DOMO Domo
$78.15 /

+1.26 (+1.64%)

DOMO Domo
$78.15 /

+1.26 (+1.64%)

DOMO Domo
$78.15 /

+1.26 (+1.64%)

Recommendations
Whitbread price target raised to 3,700 GBp from 3,500 GBp at Morgan Stanley » 13:05
06/18/21
06/18
13:05
06/18/21
13:05
WTBDY

Whitbread

$11.64 /

-0.12 (-1.02%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WTBDY Whitbread
$11.64 /

-0.12 (-1.02%)

06/10/21 Peel Hunt
Whitbread upgraded to Add from Hold at Peel Hunt
05/24/21 Deutsche Bank
Whitbread price target lowered to 3,800 GBp from 4,010 GBp at Deutsche Bank
05/14/21 Morgan Stanley
Whitbread upgraded to Overweight from Equal Weight at Morgan Stanley
04/28/21 Societe Generale
Whitbread price target lowered to 3,823 GBp from 3,888 GBp at Societe Generale

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.